Harmony Biosciences names COO Peter Anastasiou CEO effective Jan. 1, 2027

• Harmony Biosciences named Peter Anastasiou as president, CEO, board member effective Jan. 1, 2027; he is senior EVP and COO.
• Anastasiou previously served on Harmony’s board; background includes more than three decades in biopharma commercializing, acquiring, developing CNS treatments.
• Jeffrey M. Dayno will retire as president and CEO on Dec. 31, 2026; he will step down from the board.
• Dayno will serve as a non-executive adviser through 2027 during the leadership transition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120700PRIMZONEFULLFEED9843421) on October 12, 2026, and is solely responsible for the information contained therein.